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the radiation response of patients diagnosed with locally advanced non-small-cell lung
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Background/aim: This study aimed to investigate the effect of chemoradiotherapy (CRT) on interferon-gamma (IFN-γ), interleukin-6
(IL-6), and tumor necrosis factor-alpha (TNF-α), which are critical markers of the clinical radiation response of patients with locally
advanced non-small-cell lung cancer (NSCLC) and glioblastoma multiforme (GBM).
Materials and methods: Thirty patients who were treated with CRT and 20 healthy controls were prospectively evaluated. Circulating
levels of cytokines were measured by enzyme-linked immunosorbent assay procedure. Post-CRT and pre-CRT levels were compared.
Results: Post-CRT, TNF-α and IFN-γ levels were significantly lower than pre-CRT levels in the NSCLC and GBM groups, respectively.
The statistical analysis did not show any significant difference between the post- and pre-CRT IL-6 levels. However, the pre-CRT IL-6
levels in the GBM group and post-CRT IL-6 levels in the NSCLC group were significantly higher than those of the control group.
Conclusion: CRT affected TNF-α levels in NSCLC and IFN-γ levels in GBM, with the levels of both decreasing significantly. The IL-6
levels of the post-CRT NSCLC group were higher than those of the post-CRT GBM group. Irradiation-induced IL-6 may be responsible
for tumor regrowth. Therefore, treatment with IL-6 inhibitors could be a potential therapeutic strategy for sensitizing NSCLC to
irradiation in the clinic.
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1. Introduction
Lung cancer is a leading cause of mortality. The most
common cancer subtype, non-small-cell lung cancer
(NSCLC), accounts for 85%–90% all cases of NSCLC,
which is mainly caused by environmental and genetic
factors (1). Chronic inflammatory conditions have been
reported to play an important role in the progression of
lung cancer (2–4). Despite recent advances in treatment,
the prognosis of patients with NSCLC remains poor, with
5-year overall survival of approximately 15% (5). NSCLC
typically presents at an advanced stage, where multimodal
therapy, including systemic therapy, radiotherapy (RT), and
surgery, is necessary (6).
Glioblastoma multiforme (GBM) is one of the most
malignant neoplasms in humans (7). Despite multimodal
treatment consisting of debulking surgery, RT, and
chemotherapy (CT), the prognosis remains extremely poor,
with a median survival of 14.6 months (8). There is an
urgent, unmet need for novel, effective therapeutic strategies
* Correspondence: c.d.cetinkaya@gmail.com

for this devastating diseases so several immunotherapies
are under development (9).
RT is used to treat patients with NSCLC and GBM.
Cellular damage caused by ionizing radiation induces
specific proteins involved in DNA repair, cell death,
inflammation, and other pathophysiological responses (10).
The majority of biomarker studies in radiation oncology
have focused on predicting tumor responses and survival
(10,11).
The plasma levels of a range of cytokines have been
investigated in both murine (12) and cell models (13).
Proinflammatory cytokines that are expressed as acute
phase reactants include tumor necrosis factor-α (TNF-α),
interleukin-1 (IL-1), and interleukin-6 (IL-6) (14–17).
IL-6 is a multifunctional cytokine that plays an important
role in a wide range of biological activities in different types
of cells, including tumor cells. IL-6 is involved in the host
immune defense mechanism, as well as in the modulation
of growth and differentiation in various malignancies (18).
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TNF-α is a proinflammatory cytokine inducing a broad
range of cellular responses, ranging from inflammatory
cytokine production to cell survival, cell proliferation, cell
differentiation, and cell death. TNF-α can trigger different
forms of programmed cell death that are morphologically
distinguished as apoptosis and necroptosis (19).
Interferon gamma (IFN-γ), a cytokine secreted by
activated T cells and natural killer cells, exhibits dramatic
antiviral, antitumor and immunomodulation effects by
enhancing the activity of immune cells, upregulating
antigen presentation, and increasing the sensitivity of
tumor cells to apoptotic signals (20).
The inflammatory response is a classical feature of
radiation exposure (21). RT may result in the onset of local
inflammation and an acute phase reaction, which causes
radiation-related toxicity. Ionizing radiation is known to
damage cells within the irradiated volume by generating
oxygen species and cytokine-mediated multicellular
interactions (22).
To shed light on the association between ionizing
irradiation and the induction of inflammatory response,
circulating levels of IFN-γ, IL-6, and TNF-α were measured
in a group of patients with NSCLC and GBM who were
treated with chemoradiotherapy (CRT).
2. Materials and methods
2.1. Patients
This study was approved by the Meram Medical Faculty
Ethics Committee of Necmettin Erbakan University on
01.03.2013, decision no: 2013/365. All the participants
provided written informed consent. Blood samples were
taken from 20 NSCLC patients, 10 GBM patients, and
20 healthy volunteers. The patients were selected from
those admitted to the Department of Radiation Oncology,
Meram Medical Faculty of Necmettin Erbakan University.
In all cases, the NSCLC was inoperable, and all the GBM
patients had postoperative residual tumors. Neither group
of patients had previously undergone CT or RT.
Heparinized blood samples were taken before and
after 6 weeks of RT and CT (temozolomide in GBM
and paclitaxel, etoposide, and carboplatin in NSCLC)
from the patients and once from the control group.
Chemotherapeutics were used for radiosensitization, not
for curative treatment. Healthy volunteers did not receive
CRT during the study.
The inclusion criteria were: 1) histologically confirmed
GBM and stage III cases of NSCLC; 2) age between 40 and
70 years with a Karnofsky Performance Status score of ≥70;
and 3) being from a similar ethnicity. Exclusion criteria
included cases of: 1) previous CT or RT experience; 2) a
secondary malignancy; 3) history of any drug addiction,
chronic smoking habit, or alcohol addiction; 4) any
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metabolic or endocrine disorders; 5) any infection; and 6)
any chronic inflammatory condition.
Plasma was separated by centrifugation at 4000 × g for
5 min. The plasma was stored at –80 °C prior to cytokine
analysis. Cytokine measurements in the control and patient
groups were studied in the Department of Biochemistry,
Meram Medical Faculty of Necmettin Erbakan University.
IFN-γ, IL-6, and TNF-α were analyzed with enzymelinked immunosorbent assay kits (Boster Biological
Technology, Fremont, CA, USA) with an ELx800 universal
microplate reader and ELx50 microplate strip washer (BioTek, Winooski, VT, USA). The cytokine levels before and
after RT were compared.
2.2. Statistical analysis
Statistical analysis was performed using SPSS for Windows
21.0 (IBM Corp., Armonk, NY, USA). The statistical
significance was calculated using general linear models.
The relationship between survival and cytokine levels
was evaluated by LR Cox regression analysis. P < 0.05 was
considered statistically significant. All the results were
expressed as mean value and standard deviation (mean ±
SD).
3. Results
IL-6 levels were reduced in GBM cases and increased in
NSCLC cases with CRT (Figure). There was a significant
difference between the pretreatment IL-6 levels of the
GBM group and those of the control group (23.93 ± 14.38
and 10.77 ± 10.48, respectively; P < 0.05). The post-CRT
IL-6 levels were significantly higher in the NSCLC group
compared with those of the control group (22.55 ± 14.82
and 10.77 ± 10.48, respectively; P < 0.05).
With CRT, TNF-α levels decreased in the patients
with NSCLC but increased in those with GBM (Figure).
Posttreatment TNF-α levels were significantly lower than
pretreatment levels in NSCLC (6.44 ± 1.74 and 12.45 ±
15.6, respectively; P < 0.05) (Table).
The levels of IFN-γ decreased in both the GBM and
NSCLC groups with CRT, but the decline was statistically
significant only in the GBM group. There was a significant
difference between the pre-CRT and post-CRT IFN-γ
levels of the patients with GBM (8.7 ± 4.21 and 5.13 ± 3.79,
respectively; P < 0.05) (Table).
The LR Cox regression analysis revealed that the
pre-CRT and post-CRT IL-6, TNF-α, and IFN-γ plasma
levels were not significantly associated with the survival
of patients with NSCLC and GBM (P > 0.05). The values
of LR Cox regression analysis in the NSCLC and GBM
groups are presented in the Table.
4. Discussion
Recent studies have demonstrated that RT induces
immune responses (23–25) and that the altered tumor
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Figure. Cytokine levels from the start of the chemoradiotherapy (CRT) to the completion of CRT.
The tumor necrosis factor-α (TNF-α) levels of the non-small-cell lung cancer (NSCLC) patients and interferon-γ (IFN-γ) levels of the
glioblastoma multiforme (GBM) patients decreased significantly during CRT (P < 0.05).

microenvironment contributes, in part, to the antitumor
response after RT. Although the critical roles of cytokines
in carcinogenesis have been highlighted, their roles in the
radiation response require further investigation. In the
present study, we analyzed radiation-induced changes in
IFN-γ, IL-6, and TNF-α levels to investigate the usefulness
of cytokines as a marker during RT, and we examined
the relationship between survival and cytokine levels in
NSCLC and GBM patients.
A reduction in IL-6 levels can sensitize tumor cells
to irradiation by increasing cell death and DNA damage,

and it can mitigate tumor regrowth after irradiation
(26). Lopes and Callera (27) demonstrated that IL-6 was
sensitive to irradiation in patients with prostate cancer,
in contrast to IL-2, IL-4, IL-5, IL-6, TNF-α, macrophage
inflammatory protein-1-alpha, and leukemia inhibitory
factor. The increased levels of IL-6 following RT, without
concurrent elevation of those of the other cytokines
involved in the acute phase reaction, are not typical of the
classical inflammatory response to radiation exposure.
In the present study, the plasma IL-6 level of both cancer
groups was higher than that of the control group. During
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Table. The pre-chemoradiotherapy (CRT) and post-CRT levels of interferon-γ (IFN-γ) interleukin-6 (IL-6), and tumor necrosis factor-α
(TNF-α) in the groups.

Mean ± SD

P-value

HR

95.0% CI,
lower–upper

Pre-CRT IL-6
NSCLC
GBM
Control

18.39 ± 8.61
23.93 ± 14.38 a
10.77 ± 10.48

0.404
0.152

1.032
1.071

0.958–1.111
0.975–1.177

Pre-CRT TNF-α
NSCLC
GBM
Control

12.45 ± 15.6
8.69 ± 5.26
9.89 ± 10.12

0.702
0.430

1.007
0.946

0.974–1.041
0.824–1.086

Pre-CRT IFN-γ
NSCLC
GBM
Control

10.48 ± 12.7
8.7 ± 4.21
9.7 ± 7.27

0.282
0.406

0.946
1.156

0.854–1.047
0.821–1.629

Post-CRT IL-6
NSCLC
GBM

22.55 ± 14.82 a
17.75 ± 12.47

0.603
0.188

1.012
1.044

0.968–1.057
0.979–1.113

Post-CRT TNF-α
NSCLC
GBM

6.44 ± 1.74 b
10.15 ± 6.99

0.443
0.687

1.109
1.037

0.851–1.444
0.868–1.240

Post-CRT IFN-γ
NSCLC
GBM

8.91 ± 7.84
5.13 ± 3.79 b

0.121
0.350

1.054
0.907

0.986–1.126
0.738–1.113

Survival
NSCLC
GBM

287.8 ± 193.8
466.7 ± 377.46

-

-

-

SD, Standard deviation; HR, hazard ratio; CI, confidence interval; NSCLC, non-small-cell lung cancer; GBM, glioblastoma multiforme.
The P-value, HR, and 95.0% CI values for survival (days) and cytokine levels in the LR Cox regression analysis are presented. The IFN-γ,
IL-6, and TNF-α levels were not associated with patient survival.
a
Significantly different when compared with the control group (P < 0.05).
b
Significantly different when compared with pre-CRT levels (P < 0.05).

CRT, IL-6 decreased in the GBM group and increased in
the NSCLC group. One question arising from our results
is why we did not observe the same changes in IL-6 levels
among patients with GBM and NSCLC. Usually, the total
volume of irradiated tissue is assumed to influence the
development of tissue injury. In our study, the IL-6 levels
of the post-CRT NSCLC group were higher than those of
the post-CRT GBM group. This difference in the levels of
post-CRT IL-6 levels in each type of cancer may be due to
differences in the irradiated tissue volume. Furthermore,
in vitro and in vivo experiments have demonstrated
that the expression of IL-6 was linked to irradiation and
radiation resistance (28,29).
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Chen et al. (26) demonstrated that IL-6 was important
in determining the radiation response of liver tumor cells.
Given the potential role of irradiation-induced IL-6 in tumor
regrowth, they proposed that concurrent treatment with
IL-6 inhibitors could be a potential therapeutic strategy for
increasing the radiation response of tumors. Chen et al. (30)
also explored the predictive power of IL-6 in the treatment
response of pharyngeal cancer, and they suggested that
regulating IL-6 signaling might be a promising therapeutic
approach. In our study, the post-CRT level of IL-6 was
significantly higher in the NSCLC group compared with
that of the control group. An antibody targeting IL-6 might
be useful in NSCLC patients undergoing RT.
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Several clinical trials have demonstrated the
therapeutic effects of human interferons on malignancies
and infectious diseases. The effects of IFN alone or
combined with other treatment modalities (RT and CT)
in NSCLC have been investigated. Arpin et al. reported
that IFN-γ did not display cytotoxic activity and that it may
actually induce repair mechanisms (31). We found that
IFN-γ levels significantly decreased following CRT only
in GBM. Due to decreased levels of IFN-γ after CRT, we
propose that integrating immunotherapy in the primary
standard treatment for GBM might benefit patients.
Combining cytotoxic therapy with glioma vaccination has
been conducted, and encouraging preliminary efficacy
has been reported (32,33). Ardon et al. (34) concluded
that including tumor vaccination as part of the standard
primary postoperative treatment for patients with newly
diagnosed GBM was feasible and that it was well tolerated.
Two distinct apoptotic pathways have been
identified: the intrinsic and the extrinsic pathway (35).
In the extrinsic pathway, cell surface death receptors are
activated by specific ligands such as TNF-α (36). It is well
known that both pathways are involved in radiationinduced apoptosis (37). Certain NSCLCs have been
shown to be resistant to current therapeutic approaches
due to defects in apoptotic mechanisms. Overexpression
of inhibitors of apoptosis proteins was shown to be
associated with resistance to conventional therapies (e.g.,
RT) and poor patient outcomes. Inhibitors of apoptosis
proteins modulated nuclear factor-kappa B signaling and
inhibited TNF-α-mediated cancer cell apoptosis. Recently
several Smac mimetics have been introduced to eliminate
resistance to ionizing radiation (IR). According to one
study, Debio 1143 was shown to be a potent sensitizer
of NSCLC cells to effects of IR-induced apoptosis and it
remarkably enhanced the radiosensitivity by autocrine
TNF-α production. Furthermore, it has been detected
that the radiosensitization effects could be potentiated
by an increase in TNF-α stimulation (6). In another
study, El-Mesery et al. (26) reported that novel second
mitochondria-derived activator of caspases mimetic BV6
induces cell death and sensitizes different cell lines to TNFα-induced apoptosis (38). In the present study, the levels
of TNF-α decreased with CRT in the NSCLC patients.
Therapies that promote the sensitization to RT when used
alone or in combination with existing modalities could be
promising.

We also evaluated the relationship between patient
survival and cytokine levels to determine the potential role
of the latter in the prognosis of patients. Arpin et al. (39)
correlated variations in IL-6 and TNF-α levels with the
occurrence of radiation pneumonitis during RT in patients
with NSCLC to evaluate the predictive value of cytokine
levels. They suggested that early variations in circulating
IL-6 and IL-10 levels during RT were significantly
associated with the risk of radiation pneumonitis. In a
clinical study, Shariat et al. (40) found that plasma IL-6
levels were significantly elevated in patients with prostate
cancer that had metastasized to the bones, and they
observed that preoperative plasma IL-6 levels predicted
biochemical progression and lymph node metastases
in men following radical prostatectomy (41). However,
according to our study, pre-CRT and post-CRT IFN-γ,
IL-6, and TNF-α plasma levels were not significantly
associated with the survival of patients with NSCLC and
GBM. This finding may be due to the small sample size in
our study.
In conclusion, the present study was undertaken to
examine the effect of CRT on the levels of cytokines in
patients with NSCLC and GBM. Our data demonstrated
that IFN-γ, IL-6, and TNF-α were sensitive to irradiation.
Within the framework of the present study, the significantly
decreased levels of TNF-α in NSCLC and IFN-γ in GBM
following RT did not suggest a classical inflammatory
response to radiation exposure. The levels of IL-6 were
high in both NSCLC and GBM cases when compared to the
control group, but they decreased in GBM and increased
in NSCLC during CRT. Given that the GBM and NSCLC
patients in this study received the same doses of RT, it is
unusual that the IL-6 levels of the two groups differed in
response to the treatment. Further studies with a larger
number of cases should be designed to elucidate the roles
of IFN-γ, IL-6, and TNF-α as biomarkers of malignancy
and to discover new anticancer strategies.
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